The level of proangiogenic factor VEGF was analyzed during treatment, and it was found that in 60% of IBC patients (subgroup 1), the VEGF level remained high (350 pg/ml) after therapy, indicating the tumor's aggressiveness and ineffective neoadjuvant treatment. The gene discussed is VEGFA; the disease is neoplasm.